New drug combo trial aims to shrink advanced stomach tumors
NCT ID NCT07390383
Summary
This study is testing whether a new drug called LBL-024, when combined with other cancer drugs, can help shrink tumors in adults with advanced stomach or gastroesophageal junction cancer. It will enroll about 110 participants to measure how well the tumors respond to treatment and to check the safety of the drug combination. This is a Phase 2 trial, meaning researchers are gathering evidence on whether the treatment works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOUR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, 030013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, 266000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Fourth Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300202, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.